Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
L Vercellino, R Di Blasi, S Kanoun, B Tessoulin… - Blood …, 2020 - ashpublications.org
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
[HTML][HTML] Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis
Chimeric antigen receptor T cell (CAR-T) therapy is approved for treatment of
relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). Here we evaluate whether …
relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). Here we evaluate whether …
[HTML][HTML] Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma
MS Hoffmann, BD Hunter, PW Cobb, JC Varela… - … and Cellular Therapy, 2023 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …
[HTML][HTML] Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
RJ Lin, SM Lobaugh, M Pennisi, HT Chan… - …, 2021 - ncbi.nlm.nih.gov
Large B-cell lymphoma (LBCL) predominantly affects older adults with generally suboptimal
outcomes even when treated with curative intent. 1 In the relapsed/refractory setting, the …
outcomes even when treated with curative intent. 1 In the relapsed/refractory setting, the …
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
G Shouse, A Kaempf, MJ Gordon, A Artz… - Blood …, 2023 - ashpublications.org
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
Y Zhang, Y Wang, Y Liu, C Tong, C Wang, Y Guo, D Ti… - Leukemia, 2022 - nature.com
Increasing the remission rate and reducing the recurrence rate can improve the clinical
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
D Sermer, C Batlevi, ML Palomba, G Shah… - Blood …, 2020 - ashpublications.org
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …
[HTML][HTML] Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy
M Byrne, OO Oluwole, B Savani, NS Majhail… - Biology of Blood and …, 2019 - Elsevier
Most patients with large cell lymphoma are cured with frontline chemoimmunotherapy. For
individuals with refractory disease and those who relapse after conventional therapies …
individuals with refractory disease and those who relapse after conventional therapies …
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
Corticosteroids are commonly used for the management of severe toxicities associated with
chimeric antigen receptor (CAR) T-cell therapy. However, it remains unclear whether their …
chimeric antigen receptor (CAR) T-cell therapy. However, it remains unclear whether their …